SCHEMBL8495606

SCHEMBL8495606

CNc1ccccc1SC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
MAPT P10636 4/20 0.46
HSD17B10 Q99714 3/20 0.46
POLB P06746 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
KDM4E B2RXH2 1/20 0.46
USP2 O75604 1/20 0.46
HPGD P15428 1/20 0.46
RECQL P46063 1/20 0.46
TP53 P04637 1/20 0.43
NPC1 O15118 1/20 0.42
LMNA P02545 1/20 0.42
RAB9A P51151 1/20 0.42
MAPK1 P28482 1/20 0.42
TSHR P16473 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8897003 0.84 CETP (0.48) ALDH1A1KMT2AMEN1MAPTHSD17B10
SCHEMBL6244315 0.84 L3MBTL1 (0.46) ALDH1A1SMN1; SMN2KMT2AMEN1MAPT
SCHEMBL31231922 0.81 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2KMT2AMEN1MAPT
SCHEMBL18684672 0.80 POLB (0.43) ALDH1A1SMN1; SMN2KMT2AMEN1MAPT
SCHEMBL23875800 0.77 KMT2A (0.50) ALDH1A1SMN1; SMN2KMT2AMEN1MAPT
SCHEMBL7349 0.77 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2KMT2AMEN1MAPT
SCHEMBL29573636 0.77 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2KMT2AMEN1MAPT
SCHEMBL21032591 0.77 ADRA1D (0.47) ALDH1A1SMN1; SMN2KMT2AMEN1MAPT
SCHEMBL14383870 0.77 ADRA2A (0.46) ALDH1A1SMN1; SMN2MAPTHSD17B10POLB
SCHEMBL24181427 0.77 POLB (0.42) ALDH1A1SMN1; SMN2KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240217974-A1 ISOQUINOLONE COMPOUND AND USE THEREOF JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) 2024-07-04 US disclosed
US-20230174485-A1 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2023-06-08 US disclosed
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS INC (US) 2023-05-11 US disclosed
WO-2023064584-A1 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS VANDERBILT UNIVERSITY (US) 2023-04-20 WO disclosed
US-20230118497-A1 PYRAZOLE-CONTAINING POLYCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2023-04-20 US disclosed
EP-3495358-B1 AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES BRISTOL MYERS SQUIBB CO (US) 2022-04-27 EP disclosed
WO-2021228173-A1 AZEPINE FUSED RING COMPOUNDS AND MEDICAL USES THEREOF 中国医药研究开发中心有限公司 2021-11-18 WO disclosed
WO-2021195346-A1 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2021-09-30 WO disclosed
US-11014904-B2 1,2,4-triazine-3-amine derivative, preparation method therefor, and use thereof in medicine JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2021-05-25 US disclosed
US-20210107908-A1 PHARMACEUTICAL COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-04-15 US disclosed
US-7390822-B2 Substituted 4-phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives for reducing ischaemic damage JANSSEN PHARMACEUTICA, N.V. (BE) 2008-06-24 US disclosed
US-7390822-B2 Substituted 4-phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives for reducing ischaemic damage JANSSEN PHARMACEUTICA, N.V. (BE) 2008-06-24 US disclosed
US-20080096925-A1 Novel Substituted 4-Phenyl-4[H-Imidazol-2-YL]-Piperidine Derivatived And Their Use As Selective Non-Peptide Delta Opioid Agonists JANSSEN PHARMACEUTICA N.V. (BE) 2008-04-24 US disclosed
US-20080096925-A1 Novel Substituted 4-Phenyl-4[H-Imidazol-2-YL]-Piperidine Derivatived And Their Use As Selective Non-Peptide Delta Opioid Agonists JANSSEN PHARMACEUTICA N.V. (BE) 2008-04-24 US disclosed
US-7282508-B2 Substituted 4-phenyl-4-(1H-imidazol-2-yl)-piperidine derivatives and their use as selective non-peptide delta opioid agonists JANSSEN PHARMACEUTICA N.V. (BE) 2007-10-16 US disclosed
US-7282508-B2 Substituted 4-phenyl-4-(1H-imidazol-2-yl)-piperidine derivatives and their use as selective non-peptide delta opioid agonists JANSSEN PHARMACEUTICA N.V. (BE) 2007-10-16 US disclosed
EP-0903341-A1 \"Novel ortho-mercaptoaniline compounds\ Akzo Nobel N.V. (NL) 1999-03-24 EP disclosed
EP-0169101-B1 PROCESS FOR PREPARING (HYDROCARBYLTHIO)CYCLIC AMINES ETHYL CORPORATION (US) 1988-08-24 EP disclosed
US-4594453-A Reacting hydrocarbyl disulfide with aromatic amine ETHYL CORPORATION (US) 1986-06-10 US disclosed
EP-0169101-A1 Process for preparing (hydrocarbylthio)cyclic amines ETHYL CORPORATION (US) 1986-01-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210107908-A1 PHARMACEUTICAL COMPOUNDS MAPT, CYP3A5, SLC5A1 ALDH1A1 703/4885SMN1; SMN2 1717/4885KMT2A 2886/4885
US-20230118497-A1 PYRAZOLE-CONTAINING POLYCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF P2RX3, P2RX7, P2RX4 ALDH1A1 1184/4885SMN1; SMN2 3398/4885KMT2A 4250/4885
US-20080096925-A1 Novel Substituted 4-Phenyl-4[H-Imidazol-2-YL]-Piperidine Derivatived And Their Use As Selective Non-Peptide Delta Opioid Agonists OPRD1, OPRK1, OPRL1 ALDH1A1 1647/4885SMN1; SMN2 1013/4885KMT2A 3747/4885
US-20240217974-A1 ISOQUINOLONE COMPOUND AND USE THEREOF CYP4A11, CYP11B2, NQO1 ALDH1A1 708/4885SMN1; SMN2 3753/4885KMT2A 1050/4885
US-20230174485-A1 LIPOXYGENASE INHIBITORS ALOX15B, ALOX12, ALOX15 ALDH1A1 133/4885SMN1; SMN2 1035/4885KMT2A 2425/4885
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY MYC, MYCBP, MYCBP2 ALDH1A1 2768/4885SMN1; SMN2 3495/4885KMT2A 3918/4885
US-11014904-B2 1,2,4-triazine-3-amine derivative, preparation method therefor, and use thereof in medicine ADORA2B, ADORA2A, ADORA1 ALDH1A1 343/4885SMN1; SMN2 3922/4885KMT2A 2404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.